· Regulation · Regulation Desk
Health Canada cleared generic semaglutide hundreds of dollars below Novo's price while US patents block US generics until 2031. The patent thicket, compounding cliff, and import-personal-use rules explained.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.